ducovest

DRUG:AU:AU-BetaShares Global Healthcare Currency Hedged (AUD)

ETF | Others |

Last Closing

USD 8.67

Change

+0.13 (+1.52)%

Market Cap

USD 0.16B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Currency: AUD

Country : Australia

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

N/A

 USD 14.72B
IVV:AU iShares Core S&P 500 AUD

N/A

 USD 7.65B
VGS:AU Vanguard MSCI International Sh..

N/A

 USD 7.36B
QUAL:AU VanEck Vectors MSCI World ex A..

N/A

 USD 5.58B
IOZ:AU Ishares Core S&P/Asx 200

N/A

 USD 5.44B
STW:AU SPDR® S&P/ASX 200 Fund

N/A

 USD 5.14B
NDQ:AU Betashares Nasdaq 100

N/A

 USD 4.86B
HNDQ:AU BetaShares NASDAQ 100 ETF - Cu..

N/A

 USD 4.86B
A200:AU BetaShares Australia 200

N/A

 USD 4.72B
VTS:AU Vanguard US Total Market Share..

N/A

 USD 3.95B

ETFs Containing DRUG:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.47% 69% C- 73% C
Dividend Return 0.34% 14% F 6% D-
Total Return 9.81% 68% D+ 73% C
Trailing 12 Months  
Capital Gain 15.45% 63% D 73% C
Dividend Return 0.36% 3% F 2% F
Total Return 15.80% 56% F 71% C-
Trailing 5 Years  
Capital Gain 47.45% 83% B 74% C
Dividend Return 7.15% 24% F 18% F
Total Return 54.60% 81% B- 72% C
Average Annual (5 Year Horizon)  
Capital Gain 6.99% 84% B 59% D-
Dividend Return 8.40% 78% C+ 58% F
Total Return 1.41% 46% F 29% F
Risk Return Profile  
Volatility (Standard Deviation) 8.47% 75% C 94% A
Risk Adjusted Return 99.19% 98% N/A 99% N/A
Market Capitalization 0.16B 34% F 66% D+

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.